Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 666.74M P/E - EPS this Y -14.00% Ern Qtrly Grth -
Income -44.84M Forward P/E -7.48 EPS next Y -30.80% 50D Avg Chg 2.00%
Sales 500k PEG - EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 2.54 EPS next 5Y - 52W High Chg -27.00%
Recommedations 1.20 Quick Ratio 32.61 Shares Outstanding 96.94M 52W Low Chg 76.00%
Insider Own 23.21% ROA -14.75% Shares Float 44.75M Beta -
Inst Own 64.36% ROE -19.34% Shares Shorted/Prior 11.64M/12.07M Price 7.04
Gross Margin - Profit Margin - Avg. Volume 1,726,040 Target Price 25.67
Oper. Margin -3,068.00% Earnings Date Nov 7 Volume 395,063 Change -2.09%
About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc. News
12/24/24 Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green
12/19/24 ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
12/18/24 ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
12/12/24 ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
12/04/24 ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
11/27/24 US Growth Stocks With High Insider Ownership For November 2024
11/15/24 Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
11/14/24 ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...
11/13/24 ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
11/13/24 ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/12/24 ARS Pharmaceuticals announces agreement with ALK to commercialize neffy
11/11/24 ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
11/11/24 ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
11/11/24 ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
11/11/24 ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
11/06/24 Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet
11/06/24 ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
10/24/24 ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
10/18/24 Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
10/14/24 Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade
SPRY Chatroom

User Image RoyMunson69 Posted - 3 hours ago

$SPRY Another red day nice

User Image Arroin Posted - 3 days ago

@bobbyhughes611 Thank you for your input. I really have no clue as to what initiates a BO, but I do know $SPRY and $AQST have unique products. But I figured maybe being in competition with each other would cut potential profits for both.

User Image S_Franconi Posted - 3 days ago

@Marcus02 @Arrointhere I hope it will be. I'm concerned about $AQST lack of cash, it's such an outlier, but I can't imagine anyone wanting to carry a pen or spray when they can carry a tiny film. Hope I'm not wrong. Certainly $SPRY has received a lot of backing (And I think is being marketed to children and parents with a cute little name), and $AQST has some that is foreign to me for the most part.

User Image Arroin Posted - 4 days ago

$AKBA $AQST I have been thinking about BO possibilities for each of these. My thoughts are that AKBA is more likely to be BO because it has less competition for it’s product , is more affordable, and is focused more in one area. AKBA has more variety of products and it does have competition by $SPRY. Would love to hear opinions on this, or what the actual possibility of a BO is.

User Image RoyMunson69 Posted - 5 days ago

$SPRY Another red day nice

User Image Quantumup Posted - 6 days ago

H.C. Wainwright reiterated $AQST Buy; $10, after the Co announced that the FDA had granted seven years of Orphan Drug exclusivity (ODE) to Libervant (diazepam) buccal film—The FDA granted ODE to Libervant in this population based on the assessment that Libervant's buccal route of administration provides a major contribution to patient care over the rectal route of administration by providing a significantly improved ease of use. $SPRY H.C. Wainwright said in it research report:

User Image Thestocktraderhubzee Posted - 6 days ago

WATCHLIST DEC 20 2024 $GSK GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of Overall Survival Did Not Meet Statistical Significance $IONS Ionis Pharmaceuticals' TRYNGOLZA (olezarsen) Becomes First FDA-Approved Treatment For Adults with Familial Chylomicronemia Syndrome $MRK BMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105 $SPRY ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies $GIS Citigroup Maintains Neutral on General Mills, Lowers Price Target to $67

User Image BioEmerging Posted - 6 days ago

$SPRY express scripts! That’s the kind of announcement we need!

User Image RoyMunson69 Posted - 1 week ago

$SPRY The problem is their launch sucks. They aren’t going to meet estimates

User Image Mattbean Posted - 1 week ago

$SPRY thank you :)

User Image RoyMunson69 Posted - 1 week ago

$SPRY That makes no sense but congrats

User Image BlackMyth Posted - 1 week ago

$AQST $SPRY High interest rate will hurt biotech sector. I think we will see SPRY under $10 soon.

User Image Mattbean Posted - 1 week ago

$SPRY Couldn't help it. Had to buy a few hundred more at $10.75. Now waiting for $9 handle to buy a larger chunk.

User Image Mattbean Posted - 1 week ago

$SPRY Love it. $10 handle but I'm going to be greedy and wait for it to drop some more :)

User Image SHADOWxGAINZ Posted - 1 week ago

$SPRY the price action today is interesting to me

User Image Mattbean Posted - 1 week ago

$SPRY Excited! Getting close to that $10 handle so I can buy some more! :) Keep going baby!

User Image RoyMunson69 Posted - 1 week ago

$SPRY How we doin?

User Image Mattbean Posted - 1 week ago

$SPRY still not down enough. waiting for the $10 handle to buy more.

User Image RoyMunson69 Posted - 1 week ago

$SPRY Some say I am a genie

User Image BlackMyth Posted - 1 week ago

$SPRY $AQST I think Big Pharm will buy out these 2 companies because BP need a lot of fertilizer for their lawn. lol

User Image UncleRicoQB1 Posted - 1 week ago

$AQST what a fuking disaster. Now it won't even track with $IWM $XBI or $SPRY.

User Image Mattbean Posted - 1 week ago

$SPRY Good :)

User Image RoyMunson69 Posted - 1 week ago

$SPRY Your wish will be granted

User Image Mattbean Posted - 1 week ago

$SPRY Please go lower this week.

User Image RoyMunson69 Posted - 1 week ago

$SPRY 250m peak sales tops. 30% of analyst pumper estimates

User Image h3ster Posted - 1 week ago

$AQST The chart for AQST has followed SPRY almost exactly for the last year. The only way it separates is with continued execution for Anaphylm and continued low revenues for $SPRY.

User Image prodigy81 Posted - 1 week ago

@Falcones $SPRY is worse than $AQST I think. The C-suite is selling in $SPRY

User Image Fireflyaway Posted - 1 week ago

$SPRY More insider selling WTF!!! 😂 $5 coming

User Image Fireflyaway Posted - 1 week ago

$SPRY Insiders still selling this 💩until $5

User Image Falcones Posted - 1 week ago

$AQST Can’t be coincidence that $SPRY is also falling last couple of days. What’s going on 🧐.

Analyst Ratings
Leerink Partners Outperform Sep 20, 24
Cantor Fitzgerald Overweight Sep 16, 24
Cantor Fitzgerald Overweight Sep 9, 24
Cantor Fitzgerald Overweight Aug 20, 24
Raymond James Strong Buy Aug 13, 24
Raymond James Outperform Jul 25, 24
Wedbush Outperform Mar 11, 24
Leerink Partners Outperform Mar 5, 24
Wedbush Outperform Nov 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shawver Laura Director Director Sep 01 Sell 7.71 100,000 771,000 210,346 09/05/23
Shawver Laura Director Director Sep 01 Option 1.27 100,000 127,000 310,346 09/05/23
RA CAPITAL MANAGEMENT, L.P. Director Director Aug 29 Buy 6.20 3,750,000 23,250,000 5,856,774 08/31/23
ORBIMED ADVISORS LLC Director Director Aug 29 Buy 6.20 500,000 3,100,000 8,019,187 08/31/23
Thompson Peter A. Director Director Aug 29 Buy 6.20 500,000 3,100,000 8,019,187 08/31/23
Shawver Laura Director Director Aug 03 Sell 7.04 45,004 316,828 210,346 08/07/23
Shawver Laura Director Director Aug 03 Option 1.27 45,004 57,155 229,243 08/07/23
Shawver Laura Director Director Aug 01 Sell 7.14 54,996 392,671 210,346 08/03/23
Shawver Laura Director Director Aug 01 Option 1.27 54,996 69,845 246,627 08/03/23
Shawver Laura Director Director Jul 07 Sell 6.36 8,858 56,337 210,346 07/07/23
Shawver Laura Director Director Jul 07 Option 1.27 8,858 11,250 219,204 07/07/23
Shawver Laura Director Director Jul 03 Sell 6.49 91,142 591,512 210,346 07/06/23
Shawver Laura Director Director Jul 03 Option 1.27 91,142 115,750 243,856 07/06/23
Shawver Laura Director Director Jun 01 Sell 6.88 100,000 688,000 210,346 06/02/23
Shawver Laura Director Director Jun 01 Option 1.27 100,000 127,000 237,287 06/02/23
Shawver Laura Chief Executive Offi.. Chief Executive Officer Aug 05 Option 1.27 78,740 100,000 254,242 08/09/22
ROOT JONATHAN D Director Director Mar 03 Buy 30.46 2,364 72,007 2,364 03/18/22
Hawkinson Russ Sr. Vice President o.. Sr. Vice President of Finance Dec 08 Buy 21.00 200 4,200 200 02/24/22